Nephrology

Back to articles

Less is more with ESAs for chronic kidney disease

KEY POINT

According to analysis recently published in the American Journal of Kidney Diseases, erythropoiesis-stimulating agent (ESA) treatment in patients with hemoglobin levels greater than 12 g/dL is not associated with overall clinical benefit; instead, it is associated with worse clinical outcomes and significantly increased costs.

SOURCES

Clement FM et al. An economic evaluation of erythropoiesis-stimulating agents in CKD. Am J Kidney Dis. 2010;56:1050–61.